膀胱がん治療薬の世界市場研究

• 英文タイトル:Market Study on Bladder Cancer Treatment Drugs: Use of Nanotechnology to Gain Prominence Going Forward

Market Study on Bladder Cancer Treatment Drugs: Use of Nanotechnology to Gain Prominence Going Forward「膀胱がん治療薬の世界市場研究」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2301E022
• 出版社/出版日:Persistence Market Research / 2022年10月4日
• レポート形態:英文、PDF、250ページ
• 納品方法:Eメール
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥735,000 (USD4,900)▷ お問い合わせ
  Site Licence¥1,140,000 (USD7,600)▷ お問い合わせ
  Enterprisewide¥1,590,000 (USD10,600)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Persistence Market Research社の本調査レポートは、世界の膀胱がん治療薬市場の現状について調査しています。本レポートでは、エグゼクティブサマリー、市場概要、主要市場動向、主要成功要因、需要分析・予測、価格分析、市場背景、種類別(筋層非浸潤性膀胱がん、筋層浸潤性膀胱がん)分析、用途別(低悪性度腫瘍、高悪性度腫瘍)分析、流通チャネル別(病院薬局、小売薬局、その他)分析、地域別(北米、中南米、ヨーロッパ、東アジア、南アジア太平洋、中東・アフリカ)分析、構造分析、競争分析、仮定、調査方法などをまとめております。本レポートには、GlaxoSmithKline plc、Novartis International AG、Sanofi S.A、Pfizer Inc.、Eli Lilly and Co、AstraZeneca plc、Bristol-Myers Squibb、F., Celgene Corporationなどの企業情報が含まれています。
・エグゼクティブサマリー
・市場概要
・主要市場動向
・主要成功要因
・需要分析・予測
・価格分析
・市場背景
・世界の膀胱がん治療薬市場規模:種類別
- 筋層非浸潤性膀胱がんにおける市場規模
- 筋層浸潤性膀胱がんにおける市場規模
・世界の膀胱がん治療薬市場規模:用途別
- 低悪性度腫瘍における市場規模
- 高悪性度腫瘍における市場規模
・世界の膀胱がん治療薬市場規模:流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- その他の市場規模
・世界の膀胱がん治療薬市場規模:地域別
- 北米の膀胱がん治療薬市場規模
- 中南米の膀胱がん治療薬市場規模
- ヨーロッパの膀胱がん治療薬市場規模
- 東アジアの膀胱がん治療薬市場規模
- 南アジア太平洋の膀胱がん治療薬市場規模
- 中東・アフリカの膀胱がん治療薬市場規模
・構造分析
・競争分析
・仮定
・調査方法

Bladder Cancer Treatment Drugs Market: Report Scope

The latest market report by Persistence Market Research on the global bladder cancer treatment drugs market evaluates the opportunities and current market scenario, providing insights and updates about corresponding segments involved in the market for the forecast period of 2022-2032. The report provides detailed assessment of key market dynamics, and comprehensive information about the structure of the market. This study contains detailed insights into how the market is anticipated to grow during the forecast period of 2022-2032.

The primary objective of the report is to provide insights regarding opportunities in the market that are supporting the transformation of global businesses associated with Bladder Cancer Treatment Drugs. It is very important to consider that, in an ever-wavering economy, we provide estimated (Y-o-Y) year-on-year growth rate in addition to compound annual growth rate (CAGR) for overall forecasts, to enable readers better understand the analysis and evaluation of the market, and to discover lucrative opportunities in this space.

This report also provides an estimate of market size and corresponding revenue forecasts carried out in terms of absolute $ opportunity. It also offers actionable insights based on the future trends in the market. Furthermore, new and emerging players in the global bladder cancer treatment drugs market can make use of the information presented in the study for effective business decisions, which will provide momentum to their businesses as well as the global market.

The study is relevant for manufacturers, suppliers, distributors, and investors in the bladder cancer treatment drugs market. All stakeholders, as well as industry experts, researchers, journalists, and business researchers can leverage the information and data represented in the report.

Key Market Segments

Persistence Market Research’s report on the global bladder cancer treatment drugs market offers information divided into four segments – type, application, distribution channel, and region.

Type

Non-Muscle-Invasive Bladder Cancer
Muscle-Invasive Bladder Cancer
Application

Low-Grade Tumors
High-Grade Tumors
Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Others
Region

North America
Latin America
Europe
South Asia and Pacific
East Asia
Middle East and Africa
Key Questions Answered in Study

Which region will hold the highest market share over the forecast period?
Which region is experiencing the highest growth (CAGR)?
Which factors are impacting the global bladder cancer treatment drugs industry?
What are the global trends impacting the market?
What strategies must emerge players adopt to capture opportunities in various regions in the market?
What is the structure of the global bladder cancer treatment drugs market?
Research Methodology

Persistence Market Research is committed to providing unbiased market research solutions to its clients. The company follows a robust methodology for the deduction of data included in this report. A unique research methodology is utilized to conduct extensive research on the global bladder cancer treatment drugs market, and reach conclusions about the future growth factors of the market. The research methodology comprises primary research methods coupled with secondary research methods, which ensures the accuracy and reliability of the conclusions in this report.

A demand-side approach is followed to estimate the sales of target products, followed by an in-depth supply-side assessment of value generated, key trends, and events over a predefined period.

This methodology is based on standard market structures, methods, and definitions that are based on inputs from local sources in over six regions – North America, Latin America, Europe, South Asia and Pacific, East Asia, and the Middle East & Africa, which Persistence Market Research considers for segmenting the global market. Statistics, characteristics, and variances are collected at a regional level, aggregated at the same level, and then synthesized at a worldwide level, to create global market measurements.

Our main sources of research include:

Primary Research
Secondary Research
Trade Research
Social Media Research

レポート目次

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Technology Roadmap

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Key Success Factors

    4.1. Product Adoption / Usage Analysis

    4.2. Product USPs / Features

    4.3. Strategic Promotional Strategies

5. Global Bladder Cancer Treatment Drugs Market Demand Analysis 2017–2021 and Forecast, 2022–2032

    5.1. Historical Market Volume (Tons) Analysis, 2017–2021

    5.2. Current and Future Market Volume (Tons) Projections, 2022–2032

    5.3. Y-o-Y Growth Trend Analysis

6. Global Bladder Cancer Treatment Drugs Market – Pricing Analysis

    6.1. Regional Pricing Analysis By Type

    6.2. Global Average Pricing Analysis Benchmark

7. Global Bladder Cancer Treatment Drugs Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032

    7.1. Historical Market Value (US$ Mn) Analysis, 2017–2021

    7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Market Background

    8.1. Macro-Economic Factors

        8.1.1. Global GDP Growth Outlook

        8.1.2. Global Industry Value Added Overview

        8.1.3. Global Infrastructure Investment Overview

        8.1.4. Global Construction Spending Analysis

        8.1.5. Other Macro Economic Factors

    8.2. Forecast Factors – Relevance & Impact

        8.2.1. Top Companies Historical Growth

        8.2.2. GDP Growth forecast

        8.2.3. Construction Industry forecast

        8.2.4. Distribution Channel Growth Outlook

        8.2.5. Collaboration Activities

    8.3. Value Chain

        8.3.1. Raw Material Suppliers

        8.3.2. List of Manufacturers

        8.3.3. List of Distributors

    8.4. COVID-19 Crisis – Impact Assessment

        8.4.1. Current Statistics

        8.4.2. Short-Mid-Long Term Outlook

        8.4.3. Likely Rebound

    8.5. Market Dynamics

        8.5.1. Drivers

        8.5.2. Restraints

        8.5.3. Opportunity Analysis

        8.5.4. Trends

9. Global Bladder Cancer Treatment Drugs Market Analysis 2017–2021 and Forecast 2022–2032, by Type

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) and Volume Analysis by Type, 2017–2021

    9.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast by Type 2022–2032

        9.3.1. Non-Muscle-Invasive Bladder Cancer

        9.3.2. Muscle-Invasive Bladder Cancer

    9.4. Market Attractiveness Analysis by Type

10. Global Bladder Cancer Treatment Drugs Market Analysis 2017–2021 and Forecast 2022–2032, By Application

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) and Volume Analysis By Application, 2017–2021

    10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Application, 2022–2032

        10.3.1. Low-Grade Tumors

        10.3.2. High-Grade Tumors

    10.4. Market Attractiveness Analysis By Application

11. Global Bladder Cancer Treatment Drugs Market Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) and Volume Analysis By Distribution Channel, 2017–2021

    11.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Distribution Channel 2022–2032

        11.3.1. Hospital Pharmacy

        11.3.2. Retail Pharmacy

        11.3.3. Others

    11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Bladder Cancer Treatment Drugs Market Analysis 2017–2021 and Forecast 2022–2032, by Region

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017–2021

    12.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast by Region, 2022–2032

        12.3.1. North America

        12.3.2. Latin America

        12.3.3. Europe

        12.3.4. East Asia

        12.3.5. South Asia and Pacific

        12.3.6. Middle East and Africa (MEA)

    12.4. Market Attractiveness Analysis By Region

13. North America Bladder Cancer Treatment Drugs Market Analysis 2017–2021 and Forecast 2022–2032

    13.1. Introduction

    13.2. Pricing Analysis

    13.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

    13.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022–2032

        13.4.1. By Country

            13.4.1.1. U.S.

            13.4.1.2. Canada

        13.4.2. By Type

        13.4.3. By Application

        13.4.4. By Distribution Channel

    13.5. Market Attractiveness Analysis

        13.5.1. By Country

        13.5.2. By Type

        13.5.3. By Application

        13.5.4. By Distribution Channel

    13.6. Market Trends

    13.7. Key Market Participants – Intensity Mapping

    13.8. Drivers and Restraints – Impact Analysis

14. Latin America Bladder Cancer Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032

    14.1. Introduction

    14.2. Pricing Analysis

    14.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

    14.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

        14.4.1. By Country

            14.4.1.1. Brazil

            14.4.1.2. Mexico

            14.4.1.3. Rest of Latin America

        14.4.2. By Type

        14.4.3. By Application

        14.4.4. By Distribution Channel

    14.5. Market Attractiveness Analysis

        14.5.1. By Country

        14.5.2. By Type

        14.5.3. By Application

        14.5.4. By Distribution Channel

    14.6. Market Trends

    14.7. Key Market Participants – Intensity Mapping

    14.8. Drivers and Restraints – Impact Analysis

15. Europe Bladder Cancer Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032

    15.1. Introduction

    15.2. Pricing Analysis

    15.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021

    15.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

        15.4.1. By Country

            15.4.1.1. Germany

            15.4.1.2. Italy

            15.4.1.3. France

            15.4.1.4. U.K.

            15.4.1.5. Spain

            15.4.1.6. BENELUX

            15.4.1.7. Russia

            15.4.1.8. Rest of Europe

        15.4.2. By Type

        15.4.3. By Application

        15.4.4. By Distribution Channel

    15.5. Market Attractiveness Analysis

        15.5.1. By Country

        15.5.2. By Type

        15.5.3. By Application

        15.5.4. By Distribution Channel

    15.6. Market Trends

    15.7. Key Market Participants – Intensity Mapping

    15.8. Drivers and Restraints – Impact Analysis

16. South Asia and Pacific Bladder Cancer Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032

    16.1. Introduction

    16.2. Pricing Analysis

    16.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

    16.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

        16.4.1. By Country

            16.4.1.1. India

            16.4.1.2. ASEAN

            16.4.1.3. Oceania

            16.4.1.4. Rest of South Asia & Pacific

        16.4.2. By Type

        16.4.3. By Application

        16.4.4. By Distribution Channel

    16.5. Market Attractiveness Analysis

        16.5.1. By Country

        16.5.2. By Type

        16.5.3. By Application

        16.5.4. By Distribution Channel

    16.6. Market Trends

    16.7. Key Market Participants – Intensity Mapping

    16.8. Drivers and Restraints – Impact Analysis

17. East Asia Bladder Cancer Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032

    17.1. Introduction

    17.2. Pricing Analysis

    17.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

    17.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

        17.4.1. By Country

            17.4.1.1. China

            17.4.1.2. Japan

            17.4.1.3. South Korea

        17.4.2. By Type

        17.4.3. By Application

        17.4.4. By Distribution Channel

    17.5. Market Attractiveness Analysis

        17.5.1. By Country

        17.5.2. By Type

        17.5.3. By Application

        17.5.4. By Distribution Channel

    17.6. Market Trends

    17.7. Key Market Participants – Intensity Mapping

    17.8. Drivers and Restraints – Impact Analysis

18. Middle East and Africa Bladder Cancer Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032

    18.1. Introduction

    18.2. Pricing Analysis

    18.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

    18.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

        18.4.1. By Country

            18.4.1.1. GCC Countries

            18.4.1.2. Turkey

            18.4.1.3. Northern Africa

            18.4.1.4. South Africa

            18.4.1.5. Rest of Middle East and Africa

        18.4.2. By Type

        18.4.3. By Application

        18.4.4. By Distribution Channel

    18.5. Market Attractiveness Analysis

        18.5.1. By Country

        18.5.2. By Type

        18.5.3. By Application

        18.5.4. By Distribution Channel

    18.6. Market Trends

    18.7. Key Market Participants – Intensity Mapping

    18.8. Drivers and Restraints – Impact Analysis

19. Emerging Countries Bladder Cancer Treatment Drugs Market Analysis

    19.1. Introduction

        19.1.1. Market Value Proportion Analysis, By Key Countries

        19.1.2. Global Vs. Country Growth Comparison

    19.2. U.S. Bladder Cancer Treatment Drugs Market Analysis

        19.2.1. By Type

        19.2.2. By Application

        19.2.3. By Distribution Channel

    19.3. Canada Bladder Cancer Treatment Drugs Market Analysis

        19.3.1. By Type

        19.3.2. By Application

        19.3.3. By Distribution Channel

    19.4. Mexico Bladder Cancer Treatment Drugs Market Analysis

        19.4.1. By Type

        19.4.2. By Application

        19.4.3. By Distribution Channel

    19.5. Brazil Bladder Cancer Treatment Drugs Market Analysis

        19.5.1. By Type

        19.5.2. By Application

        19.5.3. By Distribution Channel

    19.6. Germany Bladder Cancer Treatment Drugs Market Analysis

        19.6.1. By Type

        19.6.2. By Application

        19.6.3. By Distribution Channel

    19.7. Italy Bladder Cancer Treatment Drugs Market Analysis

        19.7.1. By Type

        19.7.2. By Application

        19.7.3. By Distribution Channel

    19.8. France Bladder Cancer Treatment Drugs Market Analysis

        19.8.1. By Type

        19.8.2. By Application

        19.8.3. By Distribution Channel

    19.9. U.K. Bladder Cancer Treatment Drugs Market Analysis

        19.9.1. By Type

        19.9.2. By Application

        19.9.3. By Distribution Channel

    19.10. Spain Bladder Cancer Treatment Drugs Market Analysis

        19.10.1. By Type

        19.10.2. By Application

        19.10.3. By Distribution Channel

    19.11.  BENELUX Bladder Cancer Treatment Drugs Market Analysis

        19.11.1. By Type

        19.11.2. By Application

        19.11.3. By Distribution Channel

    19.12. Russia Bladder Cancer Treatment Drugs Market Analysis

        19.12.1. By Type

        19.12.2. By Application

        19.12.3. By Distribution Channel

    19.13. China Bladder Cancer Treatment Drugs Market Analysis

        19.13.1. By Type

        19.13.2. By Application

        19.13.3. By Distribution Channel

    19.14. Japan Bladder Cancer Treatment Drugs Market Analysis

        19.14.1. By Type

        19.14.2. By Application

        19.14.3. By Distribution Channel

    19.15. S. Korea Bladder Cancer Treatment Drugs Market Analysis

        19.15.1. By Type

        19.15.2. By Application

        19.15.3. By Distribution Channel

    19.16. India Bladder Cancer Treatment Drugs Market Analysis

        19.16.1. By Type

        19.16.2. By Application

        19.16.3. By Distribution Channel

    19.17. ASEAN Bladder Cancer Treatment Drugs Market Analysis

        19.17.1. By Type

        19.17.2. By Application

        19.17.3. By Distribution Channel

    19.18. Australia and New Zealand Bladder Cancer Treatment Drugs Market Analysis

        19.18.1. By Type

        19.18.2. By Application

        19.18.3. By Distribution Channel

    19.19.  GCC Countries Bladder Cancer Treatment Drugs Market Analysis

        19.19.1. By Type

        19.19.2. By Application

        19.19.3. By Distribution Channel

    19.20. Turkey Bladder Cancer Treatment Drugs Market Analysis

        19.20.1. By Type

        19.20.2. By Application

        19.20.3. By Distribution Channel

    19.21. Northern Africa Bladder Cancer Treatment Drugs Market Analysis

        19.21.1. By Type

        19.21.2. By Application

        19.21.3. By Distribution Channel

    19.22. South Africa Bladder Cancer Treatment Drugs Market Analysis

        19.22.1. By Type

        19.22.2. By Application

        19.22.3. By Distribution Channel

20. Market Structure Analysis

    20.1. Market Analysis by Tier of Companies (Linear Alpha-Olefins)

    20.2. Market Share Analysis of Top Players

    20.3. Market Presence Analysis

21. Competition Analysis

    21.1. Competition Dashboard

    21.2. Competition Benchmarking

    21.3. Competition Deep Dive

        21.3.1. GlaxoSmithKline plc

            21.3.1.1. Overview

            21.3.1.2. Product Portfolio

            21.3.1.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.1.4. Sales Footprint

            21.3.1.5. Strategy Overview

        21.3.2. Novartis International AG

            21.3.2.1. Overview

            21.3.2.2. Product Portfolio

            21.3.2.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.2.4. Sales Footprint

            21.3.2.5. Strategy Overview

        21.3.3. Sanofi S.A

            21.3.3.1. Overview

            21.3.3.2. Product Portfolio

            21.3.3.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.3.4. Sales Footprint

            21.3.3.5. Strategy Overview

        21.3.4. Pfizer Inc.

            21.3.4.1. Overview

            21.3.4.2. Product Portfolio

            21.3.4.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.4.4. Sales Footprint

            21.3.4.5. Strategy Overview

        21.3.5. Eli Lilly and Co

            21.3.5.1. Overview

            21.3.5.2. Product Portfolio

            21.3.5.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.5.4. Sales Footprint

            21.3.5.5. Strategy Overview

        21.3.6. AstraZeneca plc

            21.3.6.1. Overview

            21.3.6.2. Product Portfolio

            21.3.6.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.6.4. Sales Footprint

            21.3.6.5. Strategy Overview

        21.3.7. Bristol-Myers Squibb

            21.3.7.1. Overview

            21.3.7.2. Product Portfolio

            21.3.7.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.7.4. Sales Footprint

            21.3.7.5. Strategy Overview

        21.3.8. F., Celgene Corporation

            21.3.8.1. Overview

            21.3.8.2. Product Portfolio

            21.3.8.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.8.4. Sales Footprint

            21.3.8.5. Strategy Overview

        21.3.9. Hoffmann-La Roche AG

            21.3.9.1. Overview

            21.3.9.2. Product Portfolio

            21.3.9.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.9.4. Sales Footprint

            21.3.9.5. Strategy Overview

22. Assumptions and Acronyms Used

23. Research Methodology




• 英文レポート名:Market Study on Bladder Cancer Treatment Drugs: Use of Nanotechnology to Gain Prominence Going Forward
• 日本語訳:膀胱がん治療薬の世界市場研究
• レポートコード:MRC2301E022お問い合わせ(見積依頼・ご注文・質問)